全球心脏缺损、心脏缺陷、后鼻孔闭锁、生长迟缓、生殖器畸形和耳部畸形 (CHARGE) 综合征治疗市场 – 行业趋势和 2029 年预测

市场分析和规模

CHARGE 综合征是一种罕见疾病，每 10,000 个活产婴儿中就有 0.1-1.2 个患有该病。该病影响男性和女性，且患病人数相同，并且已在所有种族和大洲的人群中观察到。CHARGE 的发病率远远高于医学文献中记录的病例数。许多病例未得到治疗或被误诊，尤其是问题较少的儿童。CHARGE 的复发风险对于有一个患儿的父母来说较小，约为 2-3%。对于患有 CHARGE 的成年人来说，再次生下患儿的几率高达 50%。

Data Bridge Market Research 分析，2021 年心脏缺损、心脏缺陷、后鼻孔闭锁、生长迟缓、生殖器异常和耳朵异常 (CHARGE) 综合征治疗市场价值为 4.778 亿美元，预计到 2029 年将达到 6.743 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 4.40%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

CHARGE syndrome is a rare genetic condition that impairs your child's growth, coordination, behaviour, development, and intelligence. It also has an impact on the external appearance and interior organs. Surgical correction is possible for several structural problems, including choanal atresia, cleft lip, and heart malformations. Other symptoms, such as feeding difficulties and speech and language impairments, may necessitate years of treatment and other interventions. In a ventilator-dependent new-born with CHARGE syndrome who would have needed a tracheotomy, botulinum toxin A (Botox) is used to control profuse salivary secretions. Affected individuals and their families may benefit from genetic counselling. Symptomatic and supportive treatment is the only other option.

Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Dynamics

Drivers

• Increasing prevalence of CHARGE syndrome

The rising prevalence of CHARGE syndrome is estimated to enhance the market's growth rate. CHARGE syndrome is sporadic (97%) or has an autosomal dominant inheritance pattern. Gonadal mosaicism occurs in 1-2 percent of people. CHARGE syndrome is a complex disorder that manifests itself in a variety of physical and mental health issues that differ from child to child. The senses of hearing, taste, sight, smell, and touch are all affected in children with CHARGE syndrome. CHARGE syndrome is one of the most common causes of birth deafblindness.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, surging number of government initiatives to spread awareness and increasing level of disposable income will result in the expansion of coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market. Along with this, changing lifestyle of people and growing awareness about the early genetic diagnosis will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities    

The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market growth.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Scope

The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is segmented on the basis of treatment, diagnosis, route of administration, dosage form, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Botulinum toxin A
• Surgery
• Occupational Therapy
• Physical Therapy
• Speech Therapy
• Others

Diagnosis

• Genetic Testing
• Blood Tests
• Imaging Tests
• Chest X-ray
• Cranial ultrasonography
• Computed tomography (CT) scan
• Magnetic resonance imaging (MRI)
• Abdominal ultrasound
• Skeletal survey
• Echocardiography
• Others

Route of Administration

• Intradermal
• Intramuscular
• Others

Dosage Form

• Powder
• Solution

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Regional Analysis/Insights

The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, dosage form, end-users and distribution channel as referenced above.

The countries covered in the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market because of the well-established healthcare infrastructure and rising awareness among population in this region. Additionally, growing presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to increasing penetration of novel drugs and rising healthcare expenditure in this region. Also, growing government initiatives will further cushion the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Share Analysis

眼眶缺损、心脏缺陷、后鼻孔闭锁、生长迟缓、生殖器畸形和耳畸形 (CHARGE) 综合征治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对眼眶缺损、心脏缺陷、后鼻孔闭锁、生长迟缓、生殖器畸形和耳畸形 (CHARGE) 综合征治疗市场的关注有关。

心脏缺损、心脏缺陷、后鼻孔闭锁、生长迟缓、生殖器畸形和耳部畸形 (CHARGE) 综合征治疗市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（爱尔兰）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 拜耳公司（德国）
• 礼来公司 (美国)
• 默克公司（美国）
• 艾尔建（爱尔兰）
• 阿斯利康（英国）
• AbbVie Inc.（美国）
• 强生私人有限公司（美国）
• Cipla Inc.（美国）  
• 雅培（美国）
• 默克集团（德国）
• LEO Pharma A/S（丹麦）
• Bausch Health Companies Inc.（加拿大）
• 太阳制药工业有限公司 (印度)
• Aurobindo Pharma（印度）
• 鲁冰花（印度）
• Hikma Pharmaceuticals PLC（英国）
• 费森尤斯卡比公司（德国）
• Amneal Pharmaceuticals LLC.（美国）

SKU-68488